Conmed (cnmd) stock rating upgraded by bidaskclub gas efficient cars under 10000

#############

CONMED (NASDAQ:CNMD) last issued its earnings results on Tuesday, January 22nd. The medical technology company reported $0.73 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.73. CONMED had a return on equity of 9.70% and a net margin of 4.75%. The business had revenue of $242.40 million during the quarter gas efficient cars 2012, compared to analysts’ expectations of $228.40 million. During the same quarter in the previous year, the business earned $0.69 EPS. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. As a group, sell-side analysts forecast that CONMED will post 2.44 EPS for the current year.

In other news, EVP Peter K. Shagory sold 4,000 shares of the business’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $69.29, for a total transaction of $277,160.00. Following the completion of the sale, the executive vice president now owns 5,155 shares in the company electricity games, valued at approximately $357,189.95. The sale was disclosed in a document filed with the Securities Exchange o goshi technique Commission, which can be accessed through the SEC website. 3.13% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in CNMD. Bank of New York Mellon Corp lifted its position in CONMED by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 404,036 shares of the medical technology company’s stock worth $29,574,000 after acquiring an additional 3,964 shares in the last quarter. First Trust Advisors LP lifted electricity and magnetism worksheets its position in CONMED by 22.3% during the 3rd quarter. First Trust Advisors LP now owns 61,540 shares of the medical technology company’s stock worth $4,875,000 after acquiring an additional 11,210 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in CONMED by 210.0% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 6,528 shares of the medical technology company’s stock worth $503,000 after acquiring an additional 4,422 shares electricity generation capacity in the last quarter. Arizona State Retirement System lifted its position in CONMED by 3.3% during the 3rd quarter. Arizona State Retirement System now owns 37,516 shares of the medical technology company’s stock worth $2,972,000 after acquiring an additional 1,191 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in CONMED by 139.3% during the 3rd quarter. Acadian Asset Management LLC now owns 7,804 shares of the medical technology company’s stock worth $618,000 after acquiring an additional 4,543 shares in the last quarter. 95.43% of the stock is currently owned by hedge funds and other institutional investors.

CONMED Corporation, a medical technology company, develops gas key staking tool, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic gas exchange in the lungs happens by the process of, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.